What is the difference between Cerluten and Teriparatide?

Cerluten: CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration. Teriparatide: Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone

Is Teriparatide FDA approved?

Teriparatide is FDA approved (FDA status current as of 2002-11-26). This regulatory status is provided for research and educational context only.

How is Cerluten administered in research settings?

In research settings, Cerluten is typically administered via the oral or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is Teriparatide administered in research settings?

In research settings, Teriparatide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cerluten vs Teriparatide

Peptide Comparison

Cerluten vs Teriparatide

Both are Longevity & Cellular peptides.

Cerluten

brain peptide bioregulator

LongevityResearch Only

1 providers listed

Full Cerluten profile →

Teriparatide

Forteo

LongevityFDA ApprovedPrescription

Half-life: ~1 hour

3 providers listed

Full Teriparatide profile →

Bottom line

Teriparatide is FDA-approved, while Cerluten is unknown — the clearest structural difference between them.

Quick Verdict

Cerluten

Evidence

Review-level

Half-life

—

Teriparatide

Evidence

Established Clinical

Half-life

~1 hour

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Teriparatide
Further along in FDA review	Teriparatide
Oral administration option	Cerluten
More provider options (1 vs 3)	Teriparatide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cerluten

Teriparatide

Mechanism Family

Longevity & Cellular

Half-life

—

~1 hour

FDA Status

unknown

approved

Admin Routes

oral, subcutaneous

subcutaneous

Availability

Research Only

Prescription

Providers

1 listed

3 listed

FDA Update

—

Nov 2002

Avail. Notes

—

FDA-approved parathyroid hormone 1-34 analog. Forteo (NDA 021318, Nov 2002) for osteoporosis. Biosimilar Bonsity (NDA 210842, Jan 2020) also approved. Prescription only.

Research Evidence

Cerluten

Review-levelReview · 2 key studies · most recent 2022

Teriparatide

Established ClinicalMeta-analysis · 7 key studies · most recent 2026

Research Citations

Cerluten

Review2022 · International Journal of Molecular Sciences

Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium

Review2021 · Molecules

Peptide Regulation of Gene Expression: A Systematic Review

Teriparatide

Meta-analysis2026 · J Oral Biosci

The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects…

Meta-analysis2023 · Annals of Internal Medicine

Pharmacological Management of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living…

Cohort2026 · J Orthop

Association between antiosteoporosis medications and risk of sacral fracture after lumbosacral fusion in adul…

Cohort2026 · Orthop J Sports Med

Consensus on the Treatment of Midshaft Clavicular Fractures in Collegiate Football Players: A Delphi Approach…

+3 more

About Cerluten

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Research Areas

neuroprotectioncognitive supportmemoryanti-aginglongevity

About Teriparatide

Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone

Research Areas

bone formationbone density increaseosteoporosis reversalfracture risk reduction

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cerluten

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Teriparatide

Reported (Unverified — Pending Clinical Review)

osteosarcoma risk (2-year limit)Paget's diseaseprior radiation to skeletonhypercalcemia

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Cerluten

1 listed

Browse directory →

Providers offering

Teriparatide

3 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.